Diabetes represents a significant burden on society. In 2016, 415 million people worldwide suffered with this disease, leading to approximately 5 million deaths and $673 billion to $1.197 trillion in global healthcare spending. The problem is growing rapidly – by 2040, diabetes will affect an estimated 640 million people.
The chronic nature of the disease, its growing incidence, and an increasingly elderly population will converge to pose significant social and economic challenges to nations around the world, including direct costs such as inpatient hospital care and medication and indirect costs such as the loss of productivity and GDP.
Merck has made significant investments in the research and development of medications targeting diabetes and intends to pursue a strategy that will maximize benefits to global human health over the next 15 years. However, determining where and how to deploy these resources is a critical component of combating the diabetes epidemic.